Clarity Pharmaceuticals Ltd

ASX CU6.AX

Clarity Pharmaceuticals Ltd Net Income Margin for the year ending June 30, 2024: -367.83%

Clarity Pharmaceuticals Ltd Net Income Margin is -367.83% for the year ending June 30, 2024, a -46.53% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Clarity Pharmaceuticals Ltd Net Income Margin for the year ending June 30, 2023 was -251.03%, a 31.74% change year over year.
Clarity Pharmaceuticals Ltd Net Income Margin for the year ending June 30, 2022 was -367.78%, a -15.01% change year over year.
Clarity Pharmaceuticals Ltd Net Income Margin for the year ending June 30, 2021 was -319.77%, a -28.24% change year over year.
Clarity Pharmaceuticals Ltd Net Income Margin for the year ending June 30, 2020 was -249.35%, a -78.91% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

ASX: CU6.AX

Clarity Pharmaceuticals Ltd

CEO	Ms. Michelle Parker
IPO Date	Aug. 25, 2021
Location	Australia
Headquarters	National Innovation Centre
Employees	50
Sector	Healthcare
Industries Biotechnology 3D Printing Augmented Reality (AR) Clinical Trials Medical Instruments Pharmaceuticals Telehealth

Description

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Key trends

Past 5 years